Featured News

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

researchers concluded that patients with celiac disease who are infected with COVID-19 are not at higher risk of hospitalization.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.

My appointment to PCORI’s Advisory Panel on Patient Engagement has just ended. It was a productive and enlightening three-year engagement that has helped inform my ongoing service to the celiac…

The findings of the Research Opportunities in Celiac Disease Consensus Workshop, sponsored by the CDF, were published as a Research Roadmap for NIH.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

For the second consecutive year, the Celiac Disease Foundation hosted the Patient Education & Advocacy Summit.

The Celiac Disease Foundation recently published an article in Mediaplanet’s Autoimmune Diseases digital campaign.

Rep. Betty McCollum (D-MN) and Rep. Steve Stivers (D-OH) announced the formation of the Congressional Celiac Disease Caucus at the 2021 Celiac Disease Foundation Patient Education & Advocacy Summit.